Whitehawk Therapeutics to Highlight its Next-Generation ADC Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026
MWN-AI** Summary
Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a leading clinical-stage oncology therapeutics company, is poised to showcase its innovative next-generation antibody-drug conjugates (ADCs) at the 2026 American Association for Cancer Research (AACR) Annual Meeting, scheduled for April 17-22 in San Diego, CA. The company plans to present three preclinical abstracts, including an oral minisymposium and two poster presentations, demonstrating the potential benefits of its ADC portfolio.
Dr. David Dornan, Chief Scientific Officer of Whitehawk Therapeutics, stated that this marks the first time the company will unveil comprehensive preclinical proof-of-concept data for its ADC programs: HWK-007, HWK-016, and HWK-206. These programs employ advanced design features aimed at enhancing therapeutic outcomes for cancer patients. Notably, the company's preclinical data suggest these ADCs exhibit a potentially best-in-class therapeutic index among next-generation TOP1i-based ADCs, with high potency and significant tumor regression observed in xenograft studies at low dosages.
The data also highlight the favorable tolerability of Whitehawk's ADCs, which have demonstrated a high non-severely toxic dose of 60 mg/kg in non-human primate studies. This is made possible by the proprietary "carbon-bridge cysteine repairing" linker-payload technology, which maintains one of the lowest reported free payload levels in circulation.
The detailed presentation of HWK-016 will take place on April 19, 2026, while HWK-007 and HWK-206 will be presented as posters on April 21, 2026. This event represents a critical platform for Whitehawk Therapeutics to detail its pioneering advances in ADCs, with the potential to transform the landscape of treatment for challenging cancers. Further information can be found on the company's website and at the AACR meeting.
MWN-AI** Analysis
As Whitehawk Therapeutics (Nasdaq: WHWK) prepares to present its innovative next-generation antibody-drug conjugate (ADC) portfolio at the AACR Annual Meeting 2026, investors should closely monitor its developments. Scheduled for presentation from April 17-22, 2026, in San Diego, this event is pivotal for potential investors and stakeholders seeking insight into the company's clinical advancements.
Current data surrounding Whitehawk’s ADC portfolio, particularly HWK-007, HWK-016, and HWK-206, boasts promising preclinical results demonstrating high potency and tolerability. The reported low doses leading to significant tumor regression and an excellent safety profile are particularly compelling and suggest that Whitehawk may be on the brink of a breakthrough in the highly competitive oncology sector. The proprietary carbon-bridge cysteine repairing linker-payload technology positions these ADCs as likely candidates for best-in-class status, potentially catering to previously difficult-to-treat cancers.
Investors should also note Whitehawk's strategic partnership with WuXi Biologics, which adds credibility and access to expansive resources in drug development and commercialization. As the ADC landscape continues to evolve, companies that can demonstrate superior efficacy profiles and patient safety are positioned for considerable market advantage.
However, potential volatility remains a concern, as with any clinical-stage biotech firm. The pathway from preclinical findings to Phase 1 and subsequent trials presents numerous risks, including unforeseen adverse effects or regulatory hurdles. Investors are advised to review closely forthcoming clinical data and management insights during the AACR presentations.
In summary, while Whitehawk Therapeutics presents a compelling investment opportunity amidst its innovative ADC pipeline, careful consideration of the associated risks and ongoing developments is essential for informed decision-making.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
MORRISTOWN, N.J., March 17, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced it will present three preclinical abstracts, including an oral minisymposium and two posters, highlighting its next-generation antibody-drug conjugate (ADC) portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17–22, 2026, in San Diego, CA.
"For the first time, we will present comprehensive preclinical proof-of-concept for our three ADC programs, HWK-007, HWK-016 and HWK-206," said David Dornan, PhD, Chief Scientific Officer of Whitehawk Therapeutics. "These data will highlight the optimized ADC design features aimed at delivering a differentiated ADC profile with the goal of improving outcomes for cancer patients."
Whitehawk's comprehensive preclinical abstracts demonstrate a potential best-in-class therapeutic index among next-generation TOP1i-based ADCs. These data showed high potency with tumor regressions in xenograft studies at low single-digit mg/kg doses, and in non-human primate studies, Whitehawk's ADCs demonstrated a high tolerability with a highest non-severely toxic dose (HNSTD) of 60 mg/kg. Underpinning these results is one of the lowest reported free payload in circulation, driven by Whitehawk's proprietary "carbon-bridge cysteine repairing" linker-payload.
Presentation details:
HWK-016 – MUC16-Targeted ADC (Minisymposium Oral Presentation)
Title: Preclinical assessment of HWK-016, a next-generation, MUC16-targeting ADC with novel bioconjugation and linker–payload technology
Presenter: David Dornan, PhD, CSO, Whitehawk Therapeutics
Session: Advanced Antibody, Conjugate, and Targeted Therapeutic Platforms
Presentation Number: 1324
Date & Time: April 19, 2026, 3:00 – 5:00 pm
HWK-007 – PTK7-Targeted ADC (Poster Presentation)
Title: Preclinical assessment of HWK-007, a next-generation, PTK7-targeting ADC with novel bioconjugation and linker–payload technology
Presenter: Kathleen S. Keegan, PhD, VP of R&D, Whitehawk Therapeutics
Section 12: Antibody-Drug Conjugates and Linker Engineering 3
Poster Number: 4439
Date & Time: April 21, 2026, 9:00 am – 12:00 pm
HWK-206 – SEZ6-Targeted ADC (Poster Presentation)
Title: Preclinical assessment of HWK-206, a next-generation, biparatopic, SEZ6-targeting ADC with novel bioconjugation and linker–payload technology
Presenter: Kathleen S. Keegan, PhD, VP of R&D, Whitehawk Therapeutics
Section 12: Antibody-Drug Conjugates and Linker Engineering 3
Poster Number: 4440
Date & Time: April 21, 2026, 9:00 am – 12:00 pm
These abstracts are currently available on the AACR 2026 meeting website, and the presentation and posters will be accessible on the Presentations page of the Investors & News section of the Company's website at www.whitehawktx.com.
About Whitehawk Therapeutics
Whitehawk Therapeutics is a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Whitehawk's advanced three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement. More information on the Company is available at www.whitehawktx.com and connect with us on LinkedIn.
Forward Looking Statements
This press release contains certain forward-looking statements regarding the business of Whitehawk Therapeutics that are not a description of historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the Company's current beliefs and expectations and may include, but are not limited to, statements relating to expectations regarding the beneficial characteristics, optimized ADC design features, safety, efficacy, therapeutic effects and the size of the potential targeted markets with respect to the Company's ADC assets and the potential best-in-class therapeutic index among next-generation TOP1i-based ADCs. Actual results could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, uncertainties associated with preclinical and clinical development of the ADC portfolio, including failure to demonstrate the efficacy of the ADC portfolio in preclinical and clinical studies; the risk that unforeseen adverse reactions or side effects may occur in the course of testing of the ADC assets.
Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, including under the caption "Item 1A. Risk Factors," and in Whitehawk's subsequent Quarterly Reports on Form 10-Q, and elsewhere in Whitehawk's reports and other documents that Whitehawk has filed, or will file, with the SEC from time to time and available at www.sec.gov.
All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Whitehawk undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This cautionary statement is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contact:
IR@whitehawktx.com
SOURCE Whitehawk Therapeutics, Inc.
FAQ**
How does Whitehawk Therapeutics Inc. (WHWK) plan to leverage the comprehensive preclinical proof-of-concept data for its three ADC programs to attract potential partnerships or investors at the AACR Annual Meeting 2026?
What differentiating features in the ADC design does Whitehawk Therapeutics Inc. (WHWK) believe will contribute to achieving a best-in-class therapeutic index among next-generation TOP1i-based ADCs presented at the AACR?
Can Whitehawk Therapeutics Inc. (WHWK) elaborate on the significance of the low free payload levels revealed in the preclinical studies, and how this might influence patient outcomes in oncology?
How does the proprietary "carbon-bridge cysteine repairing" linker-payload technology in Whitehawk Therapeutics Inc. (WHWK) enable its ADC portfolio to overcome the limitations faced by first-generation ADCs, particularly in treating difficult cancers?
**MWN-AI FAQ is based on asking OpenAI questions about Whitehawk Therapeutics Inc. (NASDAQ: WHWK).
NASDAQ: WHWK
WHWK Trading
30.26% G/L:
$5.015 Last:
4,286,302 Volume:
$4.33 Open:
